Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04762589Phase 2Completed

RT001 in Amyotrophic Lateral Sclerosis

Role: lead

NCT07029945Phase 1Not Yet Recruiting

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Role: lead

NCT04102501Phase 3Completed

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

Role: lead

NCT04027816Completed

A Natural History Study of Infantile Neuroaxonal Dystrophy

Role: lead

NCT03570931Phase 2Active Not Recruiting

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Role: lead

NCT04937530Phase 2Unknown

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

Role: lead

NCT02445794Phase 1Completed

A First in Human Study of RT001 in Patients With Friedreich's Ataxia

Role: lead

NCT03999814Completed

Natural History of Infantile Neuroaxonal Dystrophy

Role: lead

All 8 trials loaded